Naming conventions for research peptides and the confusion they cause

The failure mode on naming conventions for research peptides is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

I looked this up rather than remembered it, which is the right order.

Where I part company with post #9, and it is a narrow parting.

Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.

If anyone can point at the primary source I would be grateful.

The question underneath naming conventions for research peptides is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.

Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.

Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.

Two people can read the same figure differently here and both be reasonable.